My notes from the AGM indicated that key data for this trial was expected Q2 2021.

"Recruiting: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC). This is the Phase 2 Pfizer PARP inhibitor breast cancer trial the was discussed at length in the AGM yesterday. Funded 50% by Pfizer. https://clinicaltrials.gov/ct2/show/NCT03901469. A recent poster had a lot more detail on this program. Key data on this trial expected by Q2 2021."

Also, lots of other clinical activity planned for H1 2021 for Zenith. Review the AGM slide deck, my summary below, or imtesty's transcript. Links below.

https://agoracom.com/ir/ZenithEpigenetics/forums/discussion/topics/751709-summary-of-ongoing-and-planned-clinical-trials/messages/2294495#message

https://www.zenithepigenetics.com/upload/media_element/133/01/zenith-capital-corp-2020-agm-final---cc.pdf

https://agoracom.com/ir/ZenithEpigenetics/forums/discussion/topics/752331-annual-and-special-mtg-corporate-update-presentation-12-22-20-rough-transcript/messages/2296034#message